These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 35476018)

  • 1. Coronavirus Disease 2019 Vaccine Boosting in Previously Infected or Vaccinated Individuals.
    Shrestha NK; Shrestha P; Burke PC; Nowacki AS; Terpeluk P; Gordon SM
    Clin Infect Dis; 2022 Dec; 75(12):2169-2177. PubMed ID: 35476018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Necessity of Coronavirus Disease 2019 (COVID-19) Vaccination in Persons Who Have Already Had COVID-19.
    Shrestha NK; Burke PC; Nowacki AS; Terpeluk P; Gordon SM
    Clin Infect Dis; 2022 Aug; 75(1):e662-e671. PubMed ID: 35028662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance.
    Bozio CH; Butterfield KA; Briggs Hagen M; Grannis S; Drawz P; Hartmann E; Ong TC; Fireman B; Natarajan K; Dascomb K; Gaglani M; DeSilva MB; Yang DH; Midgley CM; Dixon BE; Naleway AL; Grisel N; Liao IC; Reese SE; Fadel WF; Irving SA; Lewis N; Arndorfer J; Murthy K; Riddles J; Valvi NR; Mamawala M; Embi PJ; Thompson MG; Stenehjem E
    J Infect Dis; 2023 Jun; 227(12):1348-1363. PubMed ID: 36806690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022.
    Eggink D; Andeweg SP; Vennema H; van Maarseveen N; Vermaas K; Vlaemynck B; Schepers R; van Gageldonk-Lafeber AB; van den Hof S; Reusken CB; Knol MJ
    Euro Surveill; 2022 Jan; 27(4):. PubMed ID: 35086609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of COVID-19 vaccines against ICU admission during Omicron surge in Saudi Arabia: a nationwide retrospective cohort study.
    Aldawish S; Abusaris R; Almohammadi E; Althobiti F; Albarrag A
    BMC Infect Dis; 2023 Oct; 23(1):746. PubMed ID: 37907859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of subsequent SARS-CoV-2 infection among vaccinated employees with or without hybrid immunity acquired early in the Omicron-predominant era of the COVID-19 pandemic.
    Jacobson MA; Blanc PD; Tulsky J; Tilly M; Meister R; Huen W; McNicholas JE
    Am J Ind Med; 2024 Apr; 67(4):334-340. PubMed ID: 38316635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts.
    Ballouz T; Menges D; Kaufmann M; Amati R; Frei A; von Wyl V; Fehr JS; Albanese E; Puhan MA
    PLoS One; 2023; 18(2):e0281429. PubMed ID: 36812215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.
    Muhsen K; Maimon N; Mizrahi AY; Varticovschi B; Bodenheimer O; Cohen D; Dagan R
    JAMA Netw Open; 2022 Jul; 5(7):e2219940. PubMed ID: 35796153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
    Zou Y; Huang D; Jiang Q; Guo Y; Chen C
    Front Public Health; 2022; 10():940956. PubMed ID: 35910897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the 2023-2024 Formulation of the COVID-19 Messenger RNA Vaccine.
    Shrestha NK; Burke PC; Nowacki AS; Gordon SM
    Clin Infect Dis; 2024 Aug; 79(2):405-411. PubMed ID: 38465901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Waning Neutralizing Antibody Responses Against the Omicron Variant 6 Months After Natural Severe Acute Respiratory Syndrome Coronavirus 2 Infection (With or Without Subsequent Coronavirus Disease 2019 [COVID-19] Vaccination) Versus 2-Dose COVID-19 Vaccination.
    Lim SY; Park S; Kim JY; Kim S; Jee Y; Kim SH
    Clin Infect Dis; 2022 Dec; 75(12):2243-2246. PubMed ID: 35686300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.
    Gallichotte EN; Nehring M; Stromberg S; Young MC; Snell A; Daniels J; Pabilonia KL; VandeWoude S; Ehrhart N; Ebel GD
    mSphere; 2022 Aug; 7(4):e0016922. PubMed ID: 35862798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave.
    Tan ST; Kwan AT; Rodríguez-Barraquer I; Singer BJ; Park HJ; Lewnard JA; Sears D; Lo NC
    Nat Med; 2023 Feb; 29(2):358-365. PubMed ID: 36593393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
    Gazit S; Shlezinger R; Perez G; Lotan R; Peretz A; Ben-Tov A; Herzel E; Alapi H; Cohen D; Muhsen K; Chodick G; Patalon T
    Ann Intern Med; 2022 May; 175(5):674-681. PubMed ID: 35157493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination After SARS-CoV-2 Infection Increased Antibody Avidity Against the Omicron Variant Compared to Vaccination Alone.
    LeMaster C; Geanes ES; Fraley ER; Selvarangan R; Bradley T
    J Infect Dis; 2022 Nov; 226(10):1712-1716. PubMed ID: 35714328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.